Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00866177 · ClinicalTrials.gov registry record · Phase 2
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
NCT00866177: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00866177 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 167 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00866177, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
Study Summary
This phase II trial is studying how well MEK inhibitor AZD6244 works in treating patients with stage III or stage IV melanoma. MEK inhibitor AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Selumetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2009-03 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00866177
The ClinicalTrials.gov registry entry for NCT00866177 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00866177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00866177 about?
NCT00866177 is a clinical study titled "MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma". This phase II trial is studying how well MEK inhibitor AZD6244 works in treating patients with stage III or stage IV melanoma. MEK inhibitor AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT00866177?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2009-03. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00866177?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Selumetinib (DRUG).
Who is sponsoring clinical trial NCT00866177?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.